94 related articles for article (PubMed ID: 8571734)
21. Idarubicin and cytosine arabinoside in the induction and maintenance therapy of high-risk myelodysplastic syndromes.
Invernizzi R; Pecci A; Rossi G; Pelizzari AM; Giusto M; Tinelli C; Ascari E
Haematologica; 1997; 82(5 Suppl):9-12. PubMed ID: 9402747
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
23. Haemopoietic growth factors in myelodysplastic syndromes: towards patient-oriented therapy?
Clavio M; Balleari E; Garrone A; Ballerini F; Varaldo R; Michelis GL; Balocco M; Abdall N; Colombo N; Grasso R; Gobbi M
J Exp Clin Cancer Res; 2005 Mar; 24(1):5-16. PubMed ID: 15943026
[TBL] [Abstract][Full Text] [Related]
24. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
25. Treatment with growth factors in myelodysplastic syndromes.
Geissler RG; Schulte P; Ganser A
Pathol Biol (Paris); 1997 Oct; 45(8):656-67. PubMed ID: 9569932
[TBL] [Abstract][Full Text] [Related]
26. [Myeloproliferative syndromes].
Ganser A
Ther Umsch; 1996 Feb; 53(2):97-102. PubMed ID: 8629270
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow transplantation for myelodysplasia.
Anderson JE
Blood Rev; 2000 Jun; 14(2):63-77. PubMed ID: 10913969
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia.
Ballen KK; Gilliland DG; Guinan EC; Hsieh CC; Parsons SK; Rimm IJ; Ferrara JL; Bierer BE; Weinstein HJ; Antin JH
Bone Marrow Transplant; 1997 Nov; 20(9):737-43. PubMed ID: 9384475
[TBL] [Abstract][Full Text] [Related]
29. [Role of aggressive treatment strategies for myelodysplastic syndromes].
Aul C; Germing U; Minning H; Kobbe G; Gattermann N; Südhoff T; Meckenstock G; Söhngen D; Heyll A
Praxis (Bern 1994); 1999 Mar; 88(10):431-8. PubMed ID: 10199215
[TBL] [Abstract][Full Text] [Related]
30. Treatment of pediatric myelodysplastic syndromes and juvenile myelomonocytic leukemia: the Brazilian experience in the past decade.
Valera ET; Latorre Mdo R; Mendes WL; Seber A; Lee ML; de Paula MJ; Loggetto SR; Velloso E; Niero-Melo L; Lopes LF;
Leuk Res; 2004 Sep; 28(9):933-9. PubMed ID: 15234570
[TBL] [Abstract][Full Text] [Related]
31. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.
Alessandrino EP; Amadori S; Barosi G; Cazzola M; Grossi A; Liberato LN; Locatelli F; Marchetti M; Morra E; Rebulla P; Visani G; Tura S;
Haematologica; 2002 Dec; 87(12):1286-306. PubMed ID: 12495903
[TBL] [Abstract][Full Text] [Related]
32. Sequential interleukin 3 and granulocyte-macrophage-colony stimulating factor therapy in patients with bone marrow failure with long-term follow-up of responses.
Wu HH; Talpaz M; Champlin RE; Pilat SR; Kurzrock R
Cancer; 2003 Dec; 98(11):2410-9. PubMed ID: 14635076
[TBL] [Abstract][Full Text] [Related]
33. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
34. Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.
Mori T; Aisa Y; Yokoyama A; Nakazato T; Yamazaki R; Shimizu T; Mihara A; Kato J; Watanabe R; Takayama N; Ikeda Y; Okamoto S
Bone Marrow Transplant; 2007 Feb; 39(4):217-21. PubMed ID: 17220902
[TBL] [Abstract][Full Text] [Related]
35. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
[TBL] [Abstract][Full Text] [Related]
36. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
[TBL] [Abstract][Full Text] [Related]
37. Management of the myelodysplastic syndromes.
Tricot GJ; Lauer RC; Appelbaum FR; Jansen J; Hoffman R
Semin Oncol; 1987 Dec; 14(4):444-53. PubMed ID: 2827313
[TBL] [Abstract][Full Text] [Related]
38. A patient-oriented approach to treatment of myelodysplastic syndromes.
Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
Haematologica; 1998 Oct; 83(10):910-35. PubMed ID: 9830800
[TBL] [Abstract][Full Text] [Related]
39. Treatment of myelodysplastic syndromes with cytokines and cytotoxic drugs.
Ganser A; Seipelt G; Eder M; Geissler G; Ottmann OG; Hess U; Hoelzer D
Semin Oncol; 1992 Apr; 19(2 Suppl 4):95-101. PubMed ID: 1372766
[TBL] [Abstract][Full Text] [Related]
40. [The therapy of myelodysplastic syndromes].
Aul C; Heyll A
Dtsch Med Wochenschr; 1990 Nov; 115(48):1842-50. PubMed ID: 2245768
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
